Tivic Health Systems, Inc.: directors' dealings · United States · SEC (Form 4)

About Tivic Health Systems, Inc.

Tivic Health Systems, Inc. is a United States-based company listed on the Nasdaq Capital Market under the ticker TIVC. For investors following SEC Form 4 insider transactions, Tivic is best understood as a small-cap healthcare company with an evolving identity: it began as a bioelectronic medicine and consumer medtech business, and it is now increasingly framed as an immunotherapeutics platform. Founded in 2016, the company first gained traction through ClearUP®, a handheld, non-invasive device designed to relieve sinus congestion and sinus pain. ClearUP helped establish Tivic’s early brand in the home-use health device category, with a differentiated value proposition centered on drug-free, microcurrent-based treatment. The company is headquartered in Fremont, California, United States, placing it in a strong West Coast life-sciences and medical-technology corridor. That location is relevant from an operating and capital-markets perspective, because Tivic sits at the intersection of medtech development, biotech licensing, and clinical-stage innovation. Its corporate messaging emphasizes restoring healthy immune function through bioelectronic and biologic approaches. In practical terms, that means the business has moved beyond a single-product consumer device story toward a broader platform strategy that combines device-led therapy with late-stage biologics. Tivic’s main business lines now include two distinct but related areas. First is its bioelectronic medicine / device franchise, where ClearUP remains the best-known commercial asset. Second is its biopharma pipeline, built around TLR5-based programs, including Entolimod™ and Entolasta™, which the company has described as having therapeutic and preventive potential. These candidates are associated with late-stage development and have been positioned for serious medical indications such as acute radiation syndrome. That makes the company more complex than a typical OTC device maker: it has a commercial healthtech heritage, but its future value proposition is increasingly tied to clinical development, regulatory execution, and licensing economics. From a competitive standpoint, Tivic is not a large-cap market leader. Its niche positioning depends on intellectual property, clinical differentiation, and the appeal of non-invasive or immunologically targeted therapies. In the sinus relief market, it competes against a wide array of consumer and clinical solutions. In biopharma, it competes for capital, data credibility, and regulatory progress against much better funded development-stage peers. As a result, Tivic’s equity case is typically driven more by milestones than by scale. Recent corporate developments are important. In 2025, the company announced a significant strategic transformation and expanded its clinical pipeline. In early 2026, Tivic named Michael K. Handley as CEO, after Jennifer Ernst stepped down. The company also continued to pursue financing initiatives and corporate restructuring. For francophone investors in France, Belgium, or Switzerland, Tivic Health therefore reads as a high-risk/high-upside Nasdaq healthcare microcap in the United States, with a hybrid profile spanning consumer medical devices, neuromodulation, and immunotherapeutics.